134 results
Page 2 of 7
424B5
nv6pq2w4xk d5i66uoox
3 Dec 21
Prospectus supplement for primary offering
4:06pm
FWP
q90pkh6
2 Dec 21
Free writing prospectus
12:00am
424B5
ookd3lj5
30 Nov 21
Prospectus supplement for primary offering
5:12pm
8-K
EX-10.1
t0veib0o
12 Aug 21
Entry into a Material Definitive Agreement
10:14am
8-K
EX-10.1
zt3zyw8
18 Dec 20
Entry into a Material Definitive Agreement
5:19pm
8-K
EX-99.2
5k74sf4f fu
7 Dec 20
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
8:02am
8-K
EX-99.1
x8qau9z
7 Dec 20
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
8:02am
8-K
EX-99.1
qagd4vp0p6dn
13 Oct 20
Other Events
8:11am
8-K
EX-10.1
f17yv fk2qfqo59hbo4a
25 Sep 20
Entry into a Material Definitive Agreement
4:38pm
8-K
EX-99.1
mnncnaxx fdz2mmcvg3h
27 Jan 20
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:13pm
8-K
EX-99.2
mvg1x3 olkodfbqn
23 Jan 20
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-1.1
twddub0my6 g26u
23 Jan 20
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.1
iujn4y2f1r
22 Jan 20
ImmunoGen Announces Proposed Public Offering of Common Stock
4:09pm